Other transfer or payment: SIF Stream3- Attraction
AbCellera Biologics Inc.
$225,000,000.00
Project Peregrine: Building and Accelerating Antibody Drug Development Capabilities in Canada
EF 2021-22 · 2022-03-18
Résumé
This project builds capabilities for therapeutic antibody development, fortifies early-phase clinical research infrastructure, advances biotech IP for the health and economic benefit of Canadians and enables rapid response to future pandemics.
Programme
SIF Stream3- Attraction
Bénéficiaire
Emplacement
Vancouver, British Columbia, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
838509446
Type
Other transfer or payment
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Additional Information
This is a partially repayable contribution
Additional Information (French)
Il s'agit d'une contribution partiellement remboursable
Agreement End Date
2030-03-31
Agreement Number
819720
Agreement Start Date
2022-03-18
Agreement Title
Project Peregrine: Building and Accelerating Antibody Drug Development Capabilities in Canada
Agreement Title (French)
Projet Peregrine : Renforcer et accélérer les capacités de développement de médicaments à base d’anticorps au Canada
Agreement Type
Other transfer payment
Agreement Value
$225,000,000.00
Amendment Number
0
Description
This project builds capabilities for therapeutic antibody development, fortifies early-phase clinical research infrastructure, advances biotech IP for the health and economic benefit of Canadians and enables rapid response to future pandemics.
Description (French)
Ce projet renforce les capacités de développement d'anticorps thérapeutiques, consolide l'infrastructure de recherche clinique en phase précoce, fait progresser la propriété intellectuelle en biotechnologie pour le bénéfice sanitaire et économique des Canadiens et permet une réponse rapide face aux futures pandémies.
Expected Results
The investment will allow the company to increase its capabilities in the drug development value chain to advance a portfolio of high value antibody drug targets through pre-clinical and phase 1 clinical work.
Expected Results (French)
L'investissement permettra à l'entreprise d'accroître ses capacités dans la chaîne de valeur du développement de médicaments afin de faire progresser un portefeuille de cibles de médicaments à base d'anticorps de grande valeur par le biais de travaux précliniques et de travaux cliniques de phase 1.
Federal Riding
Vancouver Granville
Federal Riding (French)
Vancouver Granville
Federal Riding Number
59036
NAICS Code
541710
Organization Code
ic
Organization
Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada
Program Name
SIF Stream3- Attraction
Program Name (French)
FIS Volet3- Attraction
Program Purpose
-Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services;-Facilitate the growth and expansion of firms in Canada;-Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.
Program Purpose (French)
-favoriser les activités de R-D qui accéléreront le transfert de la technologie et la commercialisation de produits, de processus et de services novateurs ;-faciliter la croissance et l'expansion des entreprises au Canada ;-attirer et conserver des investissements de grande envergure au Canada ; et-faire progresser la recherche industrielle, le développement et la démonstration de technologies grâce à la collaboration entre les universitaires, les organisations à but non lucratif et le secteur privé.
Recipient Business Number
838509446
Recipient City
Vancouver
Recipient Country
CA
Recipient Legal Name
AbCellera Biologics Inc.
Recipient Operating Name
AbCellera
Recipient Postal Code
V5Y0A1
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
033-2023-2024-Q1-819720